Search

Displaying results 591 - 600 of 7479 in total
  1. Drug

    Pipradrol

    go.drugbank.com/drugs/DB11584
    ApprovedWithdrawn

    Pipradrol (Meratran) [L2523] was initially developed in the 1950s as an antidepressant, however, the adverse effects associated with its use and its abuse potential led to its withdrawal and international

  2. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.

  3. Drug

    Lutropin alfa

    go.drugbank.com/drugs/DB00044
    ApprovedInvestigational

    Its pharmacological action mimics the biological activity of endogenous LH; an acute rise of LH, or LH surge, in females triggers ovulation and the development of the corpous luteum.

    Mixtures: PERGOVERIS 150 IU/75 IU ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, PERGOVERIS 150 IU/75 IU ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ VE ÇÖZÜCÜ, 3 ADETProducts: LUVERIS 75 IU, LUVERIS FOR INJECTION 75 iu/vial (Revised formula)
  4. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.

  5. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural history of SARS-CoV-2 infection and modified through targeted amino acid substitutions to exhibit an … Cilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for

  6. Drug

    Tixagevimab

    go.drugbank.com/drugs/DB16394
    ApprovedInvestigational

    hamster ovary (CHO) cells derived from a neutralizing antibody isolated from a patient with a natural history of SARS-CoV-2 infection and modified through targeted amino acid substitutions to exhibit an … Tixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for

  7. Drug

    Ceftizoxime

    go.drugbank.com/drugs/DB01332
    ApprovedWithdrawn

    A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository.

  8. Drug

    Tavaborole

    go.drugbank.com/drugs/DB09041
    Approved

    Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes … Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).

  9. Drug

    Isosorbide mononitrate

    go.drugbank.com/drugs/DB01020
    ApprovedInvestigational

    [L11743] Isosorbide mononitrate has a longer duration of action than [nitroglycerin] due to its slow onset of absorption and metabolism. … Isosorbide mononitrate is an organic nitrate with vasodilating properties.

    Synonyms: Mononitrato de isosorbida
  10. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and...